Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic Vulnerabilities.
MSMO1
cholesterol biosynthesis
drug resistance
lipidomics
metabolomics
myo-inositol
transcriptomics
triple negative breast cancer
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
31 08 2022
31 08 2022
Historique:
received:
26
07
2022
revised:
23
08
2022
accepted:
25
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
The emergence of drug resistance in cancer poses the greatest hurdle for successful therapeutic results and is associated with most cancer deaths. In triple negative breast cancer (TNBC), due to the lack of specific therapeutic targets, systemic chemotherapy is at the forefront of treatments, but it only benefits a fraction of patients because of the development of resistance. Cancer cells may possess an innate resistance to chemotherapeutic agents or develop new mechanisms of acquired resistance after long-term drug exposure. Such mechanisms involve an interplay between genetic, epigenetic and metabolic alterations that enable cancer cells to evade therapy. In this work, we generated and characterized a chemoresistant TNBC cell line to be used for the investigation of mechanisms that drive resistance to paclitaxel. Transcriptomic analysis highlighted the important role of metabolic-associated pathways in the resistant cells, prompting us to employ
Identifiants
pubmed: 36078127
pii: cells11172719
doi: 10.3390/cells11172719
pmc: PMC9454761
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Cell Mol Med. 2019 May;23(5):3711-3723
pubmed: 30920152
Int J Oncol. 2016 Jun;48(6):2415-24
pubmed: 27035231
Free Radic Biol Med. 2018 Jul;122:116-129
pubmed: 29567393
Oncol Lett. 2016 Mar;11(3):1987-1994
pubmed: 26998111
Biochem Biophys Res Commun. 2017 Jan 15;482(3):419-425
pubmed: 28212725
Nucleic Acids Res. 2014 Jan;42(Database issue):D478-84
pubmed: 24203708
Drug Resist Updat. 2017 May;32:23-46
pubmed: 29145976
CA Cancer J Clin. 2021 Jul;71(4):333-358
pubmed: 33982817
Biomedicines. 2021 Jul 26;9(8):
pubmed: 34440098
Exp Cell Res. 2016 Jul 1;345(1):37-50
pubmed: 27237097
J Lipid Res. 2004 Oct;45(10):1910-8
pubmed: 15258203
J Cell Biol. 2012 Dec 10;199(6):871-81
pubmed: 23229895
Lipids Health Dis. 2021 Feb 17;20(1):15
pubmed: 33596934
Adv Drug Deliv Rev. 2020;159:245-293
pubmed: 32711004
NPJ Breast Cancer. 2021 Dec 10;7(1):154
pubmed: 34893642
Oncol Lett. 2018 Feb;15(2):2401-2406
pubmed: 29434950
Br J Cancer. 2016 Aug 9;115(4):431-41
pubmed: 27415012
Protein Sci. 2022 Jan;31(1):47-53
pubmed: 34423492
Nat Commun. 2021 May 14;12(1):2804
pubmed: 33990571
Anal Bioanal Chem. 2018 Sep;410(23):5981-5992
pubmed: 29959482
Sci Rep. 2015 Feb 16;5:8473
pubmed: 25683757
Cancer Cell Int. 2021 Aug 10;21(1):419
pubmed: 34376211
Int J Endocrinol. 2016;2016:5616807
pubmed: 27795708
J Exp Clin Cancer Res. 2010 Feb 12;29:12
pubmed: 20152024
Elife. 2021 Jun 28;10:
pubmed: 34181531
Front Oncol. 2020 Mar 06;10:281
pubmed: 32211323
Cancer Cell. 2012 Mar 20;21(3):297-308
pubmed: 22439925
Genome Biol. 2014;15(12):550
pubmed: 25516281
Br J Cancer. 2020 May;122(11):1638-1648
pubmed: 32242101
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10166-10173
pubmed: 16801540
FEBS Open Bio. 2022 Jan;12(1):221-230
pubmed: 34775691
Cell Metab. 2018 Dec 4;28(6):833-847.e8
pubmed: 30174304
J Biol Chem. 2015 Apr 3;290(14):9101-10
pubmed: 25681445
J Lipid Res. 2012 Jan;53(1):149-57
pubmed: 22025560
Metabolites. 2020 Jul 16;10(7):
pubmed: 32708822
J Bioenerg Biomembr. 2020 Oct;52(5):321-342
pubmed: 32715369
Pharm Res. 2015 Jan;32(1):37-46
pubmed: 24962512
Clin Cancer Res. 2005 Jan 1;11(1):298-305
pubmed: 15671559
Front Pharmacol. 2019 Oct 11;10:1172
pubmed: 31680956
Metabolites. 2022 Apr 15;12(4):
pubmed: 35448542
React Oxyg Species (Apex). 2016;2(6):432-439
pubmed: 29707647
Nat Commun. 2014 Nov 12;5:5275
pubmed: 25387467
Cancers (Basel). 2021 Jul 15;13(14):
pubmed: 34298755
Sci Rep. 2021 Jan 18;11(1):1679
pubmed: 33462316
Cancer Res. 2013 Feb 1;73(3):1211-8
pubmed: 23233737
Oncol Lett. 2019 Jan;17(1):921-926
pubmed: 30655848
Semin Cancer Biol. 2022 Jan;78:90-103
pubmed: 33979674
J Am Soc Mass Spectrom. 2016 Dec;27(12):1897-1905
pubmed: 27624161
Biology (Basel). 2020 Dec 16;9(12):
pubmed: 33339398
Curr Protoc Bioinformatics. 2011 Jun;Chapter 14:Unit 14.10
pubmed: 21633943
Future Oncol. 2013 Nov;9(11):1623-36
pubmed: 24156323
Lung Cancer. 2012 Jul;77(1):9-15
pubmed: 22306125
J Biomed Sci. 2020 Feb 21;27(1):36
pubmed: 32079527
Oncol Rep. 2014 Feb;31(2):589-96
pubmed: 24297447
Breast Cancer Res Treat. 2022 Jul;194(2):231-241
pubmed: 35639264
Int J Mol Sci. 2021 Mar 21;22(6):
pubmed: 33801148
Mol Carcinog. 2019 Nov;58(11):1985-1997
pubmed: 31373074
Cancers (Basel). 2020 Aug 24;12(9):
pubmed: 32846967
Histopathology. 2007 Oct;51(4):539-46
pubmed: 17714470
Biochem Biophys Res Commun. 2015 Feb 20;457(4):614-20
pubmed: 25603057
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Oncol Res. 2020 May 29;28(3):273-284
pubmed: 31907106
Hum Pathol. 2013 Jun;44(6):1065-70
pubmed: 23266442